CONTINUATION OF THE PAJR GLOBAL CBBLE DATA FROM THE PREVIOUS LINK. 👇
[5:21 PM, 6/3/2026] hu24: The transition from child to youth to middle age is evolution in all spheres....a process, a result of internal and external factors,slow,non uniform, unique.
Lamarckism to Darwinism.
[10.06 pm, 03/06/2026] 42mpa: When uncertainty persists, responsibility does not disappear. It migrates.
Most people assume that if enough specialists become involved, enough testing is performed, enough records accumulate, and enough follow-up appointments occur, then somebody must be carrying the problem forward.
But observation and stewardship are not the same thing.
A patient can be repeatedly observed while responsibility becomes increasingly difficult to locate. Imaging can be reviewed, symptoms documented, medications prescribed, and follow-up visits completed, yet the central question can remain unanswered:
Who remains responsible when the answer is still unknown?
Over time, something subtle can happen. The patient begins tracking the timeline, remembering the findings, coordinating specialists, monitoring medications, preserving continuity, and repeatedly reconstructing the story for new audiences. The original burden remains, but a second burden quietly appears: the burden of carrying the burden.
Most discussions about healthcare focus on diagnosis, treatment, access, cost, technology, or outcomes. This case study examines something different. It explores what happens when observation continues but stewardship becomes difficult to find, and what happens when responsibility slowly migrates from institutions to the people seeking help.
Although the case itself is clinical, I suspect the phenomenon extends far beyond medicine. Complex systems of every kind struggle with the question of who remains responsible when uncertainty persists longer than expected.
Attached is a PaJR case study exploring a simple question:
What happens when observation continues, but responsibility for carrying uncertainty becomes increasingly difficult to locate?
I’m curious whether others recognize similar patterns in healthcare, education, research, law, business, or other systems where unresolved problems can outlive the structures designed to manage them.
[10:29 PM, 6/3/2026] 42mpa: Teaching point:
Most systems track the location of the problem.
Few track the location of the burden.
Reflection:
Systems are built to track problems. Human beings experience burdens.
A problem can remain visible while the burden of carrying it quietly migrates elsewhere.
When uncertainty persists, the problem remains documented in records, appointments, imaging, referrals, and follow-up plans.
But visibility does not tell us who is carrying the weight.
The patient begins preserving the timeline, remembering what changed, tracking what was tried, connecting observations, monitoring risk, and reconstructing continuity as continuity fragments.
Together, these tasks reveal a transfer.
Unresolved problems create administrative gravity, relational strain, financial pressure, interpretive labor, and future uncertainty.
When those burdens are not stewarded, they accumulate around the person already carrying the consequences.
Clinical question:
How would a system know when it is stewarding an unresolved problem versus merely documenting its existence?
Question for reflection:
What would it mean to track not only where the problem is, but who is carrying it?
[2:05 AM, 6/4/2026] hu35: Many discussions of chronic illness implicitly assume a healthcare system in which responsibility is progressively transferred to institutions: hospitals, specialist clinics, rehabilitation services, social workers, insurers, home-care agencies, and long-term care systems. The patient certainly carries a burden, but much of the operational burden is absorbed by the system.
In much of India—and in many other resource-constrained settings—the opposite often occurs.
The patient and family are not merely participants in care; they become the de facto coordinators, navigators, logisticians, financiers, record keepers, advocates, and continuity managers of care.
The burden therefore extends beyond illness itself to include:
* Finding appropriate providers.
* Obtaining appointments.
* Transporting the patient.
* Carrying records between facilities.
* Reconciling conflicting medical opinions.
* Procuring medicines and devices.
* Financing care.
* Monitoring symptoms.
* Deciding when escalation is necessary.
* Managing emergencies.
* Providing long-term physical and emotional support.
The “care pathway” exists largely in the minds and actions of families rather than in an integrated system.
The lowest-level functionaries in distributed health systems—community health workers, nurses, outreach workers, call-centre staff, referral coordinators, ambulance dispatchers, social workers, rehabilitation aides, and local volunteers—often carry a substantial moral burden of responsibility despite possessing limited formal authority.
They frequently know:
* who has missed follow-up,
* who cannot afford treatment,
* who is deteriorating,
* who failed to reach the referral centre,
* who has become lost between institutions.
Yet they often lack the resources needed to resolve these problems.
As a result, they inhabit a difficult position:
responsibility without control.
The physician may see a patient episodically.
The tertiary hospital may discharge a patient.
The specialist may complete a consultation.
But the frontline worker remains aware that the story is unfinished.
This is what you mean when you say “the loop of care rarely closes.”
In systems engineering terms, many healthcare systems are designed around episodes of care, whereas patients live through journeys of care.
The discontinuities between episodes are where much suffering accumulates.
One implication is that the burden of chronic illness should perhaps be understood as distributed across three concentric circles:
1. The patient, who experiences the illness.
2. The caregiving network, which absorbs much of the practical and emotional work.
3. The last-mile care network, which absorbs much of the continuity burden created by fragmented systems.
A fourth circle may even be added:
4. The community, which often supplies transport, financing, social support, accommodation, information, and informal caregiving.
This reframes chronic illness from an individual medical condition to a collective management problem.
[2:06 AM, 6/4/2026] hu35: ⬆️ The burden is not simply the burden of disease. It is also the burden of maintaining continuity in a system where continuity is often underprovided by formal institutions.
[7:35 AM, 6/4/2026] hu2: Again a very important discussion initiated by @42mpa
The patient bears the maximum burden of continuity because continuity is about tracking the patient's events, which are primarily happening to the patient and expressing into the patient's surroundings getting absorbed by different layers of the healthcare ecosystem as pointed out by @hu35 beginning from the immediate caregivers to those who are slightly distant such as the local offline practitioners, nurses, doctors and those who are at the maximal distance such as the global PaJR practitioners here!
[8:09 AM, 6/4/2026] 42mpa: One of the ironies of the Patient 42M observation is that the neurology resident whose anonymized portal message became part of the case study was originally from India.
Three years earlier, there is a reasonable chance he might have encountered some of the very ideas we now discuss through PaJR: continuity, stewardship, observability, and responsibility under uncertainty.
Instead, by the time Patient 42M encountered him, he had already spent three years of residency being educated by the healthcare culture of Louisiana.
The observation is not really about the resident. It is about what systems teach people to see—and what they teach people to stop seeing.
The resident did not create the pattern.
He inherited it.
My hope is that our work helps shape some of the physicians who will eventually practice here. Because if healthcare systems can transmit habits of fragmentation, educational communities can transmit habits of stewardship.
The question is which curriculum reaches them first.
[8:27 AM, 6/4/2026] hu2: Yes it's a challenge for global medical education and currently most local medical education systems every where do not encourage thinking in terms of patient centred continuity because of various reasons making fragmentation of care a global phenomenon
[9.07 am, 04/06/2026] 42mpa: Medical Liturgy began as an injury before it became theory.
Before there was a framework, there was an open wound.
Out of confusion, language slowly emerged.
There was a period of my life that felt less like healthcare and more like exile.
Medical Liturgy was born in that exile.
Long before it became a framework for recognition, continuity, stewardship, and care, it existed as a more fundamental question:
What happens to a person when suffering remains visible, documented, measurable, and still fails to become recognizable?
This excerpt comes from my first completed book, De Motu Cordis: Light in Vein.
It is the place where the first light of Medical Liturgy emerged from the darkness.
This section of the book is called:
EXILIUM MEDICAE
Medical Exile
It is not written from bitterness.
It is written from the wound.
And sometimes the wound sees the architecture long before the architecture recognizes the wound.
The pages that follow were written from the experience of being observed without being carried.
Documented without being gathered.
Reassured without being stewarded.
Seen in fragments while the whole remained unheld.
Over time, that experience became a question.
Then a language.
Then a way of thinking about care itself.
Sharing this feels vulnerable.
Not because it is unfinished.
But because it reaches back to the void from which recognition first found illumination.
Before Medical Liturgy became an idea, it was an attempt to remain legible inside a system that kept breaking the sentence.
An excerpt from De Motu Cordis: Light in Vein
[6:31 PM, 6/4/2026] 42mpa: https://www.linkedin.com/posts/colbygillespie_medicalliturgy-leadership-presenceoverperfection-activity-7468284772394643456-sEyH?utm_medium=ios_app&rcm=ACoAAEcKPFQBS7zyp1iECYDDD76fM1irYNB86q8&utm_source=social_share_send&utm_campaign=copy_link
[4:51 AM, 6/6/2026] 42mpa: I 🫀 everything about this the thought, the action, the movement, the music! ❤️🔥
[3:24 PM, 6/7/2026] hu2: This is very useful 🙏
The DPDP framework recognizes these realities.
Legitimate Use #3: Medical Treatment and Continuity of Care
Healthcare is rarely delivered by a single individual.
Treatment is collaborative.
Scenario: Cancer Care
A patient visits an oncologist.
The oncologist reviews:
Radiology reports
Pathology findings
Surgical records
Previous consultations
Treatment plans
These records may be shared among:
Medical oncologists
Radiation oncologists
Surgeons
Pathologists
Nursing teams
Tumor boards
Imagine if separate consent had to be obtained every time information moved between treating professionals.
The healthcare system would become unworkable.
Continuity of care depends on appropriate information sharing.
[6:18 PM, 6/7/2026] hu28: @hu1 @hu5 have you looked into CDSCO registration? Does PaJR fall under MDR 2017 as SaMD?
[6:22 PM, 6/7/2026] hu8: Platforms That do Fall Under SaMD: the platform will be regulated as a medical device if it performs any of the following:
[6:23 PM, 6/7/2026] hu8: Clinical Decision Support: Features algorithms that analyze patient-inputted symptoms, historical data, or vitals to suggest specific diagnoses, prognoses, or treatment plans.
Medical Device Control: The software actively drives or calculates settings for a physical medical device (e.g., dosage calculators).
Symptom Interpretation: Provides disease-specific management or treatment advice (e.g., insulin dosing recommendations based on patient logs).
[6:25 PM, 6/7/2026] hu8: Platforms That don't Fall Under SaMD: the platform will generally be exempt from SaMD regulations if it acts merely as:
[6:26 PM, 6/7/2026] hu8: Communication Infrastructure: General-purpose telehealth platforms (like video chat or messaging tools) used for routine doctor-patient consultations without diagnostic AI.
Electronic Health Records (EHR): Systems used purely for the storage, transfer, or viewing of medical information without algorithmic interpretation.
General Wellness/Communication: Standard forums, chat groups, and general peer-to-peer support groups for emotional or lifestyle support, provided they do not generate or modify medical data to guide treatment.
[6:58 PM, 6/7/2026] hu5: Hadn't looked at this earlier but above very helpful details from Prof Supten indicate it won't fall under it.
[7:12 PM, 6/7/2026] hu28: Reading above, it seems like the clinical decision support may be applicable... Evaluating patient histories and coming up with diagnosis and prognoses...
[7:14 PM, 6/7/2026] hu8: It is not crystal clear. As usual, all laws are open to subjective interpretation. That is why judgements for the same case varies from Court to Court.
[8:10 PM, 6/7/2026] hu5: I just got the below SMS a few minutes after I had read this message abd searched for CDSCO on Google. I did not click any link. I have not provided my phone anywhere.
Hello Doctor,
CDSCO Clears India’s First Locally Discovered UTI Drug - requested Article is uploaded. View here https://clrn.in?l=jg0VS-
-CLIRNET
Any idea how this could happen? Is PaJR bot using CLIRNET? @hu1
[8:28 PM, 6/7/2026] hu2: You are likely seeing this due to behavioral ad retargeting or Google Search ad extensions. Organizations use your search data to trigger sponsored text messages. [1, 2, 3]
Several factors typically cause this behavior:
1. Click-to-Message Ad Extensions
When you search for an organization on Google, you may see an ad with a "Message Us" or "Chat" button. Clicking this doesn't immediately send a text, but it opens your phone's SMS app with a pre-drafted message (e.g., "I want more information about your services"), prompting you to send it. [2, 4, 5, 6]
2. Cross-Device & Platform Retargeting
If you are logged into your Google Account across multiple devices, or if the organization's website uses tracking pixels, your search data is linked to your device profile. Advertisers can target phone numbers tied to that profile with tailored promotional SMS messages. [2, 7, 8, 9, 10]
3. Lead Generation Services
Some third-party lead generation tools scrape search engine footprints to build targeted contact lists. If your phone number is publicly associated with your professional or personal profile, you may receive promotional SMS messages from related organizations shortly after searching. [7, 11]
4. Coincidence & Spam Networks
Mass-blast spam services frequently use common topics like banking, taxes, or popular corporate brands to distribute messages. Occasionally, receiving a text about a topic you recently searched for is simply a coincidence. [7]
If you want to prevent your browsing history from being used for personalized messaging and marketing, you can adjust your tracking preferences:
* Manage your data tracking using Google's Data & Privacy settings.
* Turn off Ad Personalization in your Google Ad Settings
[6] https://www.linkedin.com/pulse/how-add-text-messaging-your-google-business-profile-localsearch-v91pc
[9:25 PM, 6/7/2026] hu15: No. PaJR doesn't use CLiRNET but CLiRNET is a known spammer. They send unsolicited sms and emails. I think it's a coincidence but you never know.
[9:28 PM, 6/7/2026] hu1: Wow!! No way. Hope you are using Private DNS and ad blocking
[10:26 PM, 6/7/2026] hu5: Had not switched to private DNS, done now.. hope dns.adguard.com is good enough?
Also use Firefox and Tailscale.
Any recommendations welcome.
[10:26 PM, 6/7/2026] hu1: Had not switched to private DNS, done now.. hope dns.adguard.com is good enough?
Also use Firefox and Tailscale.
Any recommendations welcome.
Nextdns or control D is the way to go. Although yes Adguard is very safe and based in Cyprus
[10:41 PM, 6/7/2026] hu1: .A curious problem I've encountered is that I've been blocking ads for 7 years now and I've actually lost touch with latest products and advertisements.
The other day I was taking a walk with a colleague from work and we were chatting about car insurance and I mentioned that I somehow landed a great deal because I was able to show no claims bonus discounts for 5 years straight from India and only one specific car insurance company counted this history and offered a very good deal. I had to Gemini this to find it, while my colleague casually mentioned that he was long aware of this from a YouTube ad.
I have pretty much blocked out ads in all my devices since 2019. While it has made a remarkable difference in my life in beating out spam and junk, these are the rare wins I'm maybe missing.
[10:42 PM, 6/7/2026] hu5: A curious problem I've encountered is that I've been blocking ads for 7 years now and I've actually lost touch with latest products and advertisements.
The other day I was taking a walk with a colleague from work and we were chatting about car insurance and I mentioned that I somehow landed a great deal because I was able to show no claims bonus discounts for 5 years straight from India and only one specific car insurance company counted this history and offered a very good deal. I had to Gemini this to find it, while my colleague casually mentioned that he was long aware of this from a YouTube ad.
I have pretty much blocked out ads in all my devices since 2019. While it has made a remarkable difference in my life in beating out spam and junk, these are th
Interesting perspective lol
[10:43 PM, 6/7/2026] hu1: A curious problem I've encountered is that I've been blocking ads for 7 years now and I've actually lost touch with latest products and advertisements.
The other day I was taking a walk with a colleague from work and we were chatting about car insurance and I mentioned that I somehow landed a great deal because I was able to show no claims bonus discounts for 5 years straight from India and only one specific car insurance company counted this history and offered a very good deal. I had to Gemini this to find it, while my colleague casually mentioned that he was long aware of this from a YouTube ad.
I have pretty much blocked out ads in all my devices since 2019. While it has made a remarkable difference in my life in beating out spam and junk, these are th
My observation is also that because these ads are now taken off, I'm far more productive and volitional with my time than most others. Far more deliberate with money spending too.
Prompt - incidence of bicarbonate use in patients with ckd in our database
Answer - In our database, the use of bicarbonate in patients with Chronic Kidney Disease (CKD) is primarily documented in the context of managing metabolic acidosis and acute metabolic crises.
📋 CLINICAL CONTEXTS OF BICARBONATE USE
Management of Metabolic Acidosis: Bicarbonate therapy is frequently employed to correct acidosis, which is a common complication in advanced CKD. It is often administered as an oral supplement (e.g., Sodium Bicarbonate 1g TID) to maintain acid-base balance and slow the progression of renal osteodystrophy and associated complications.
37 yr female with CKD
Evidence based date wise workflow logs
Acute Metabolic Crises (DKA): In patients with co-existing Type 1 Diabetes and CKD, bicarbonate is used during episodes of Diabetic Ketoacidosis (DKA) when serum bicarbonate levels drop significantly. This is a critical intervention to mitigate the systemic effects of severe acidemia.
23F HEART FAILURE WITH DELAYED PUBERTY, TYPE-1 DM 13 years Telangana PaJR
Evidence-Based Practice: Clinical appraisals within our records highlight the role of oral sodium bicarbonate in older patients with CKD and low-grade acidosis, noting its potential impact on physical function and long-term outcomes.
Critical appraisal
💡 CLINICAL NOTE: The decision to initiate bicarbonate therapy in CKD patients is highly individualized, balancing the need to correct metabolic acidosis against the risks of volume overload and hypertension. Close monitoring of electrolytes and acid-base status is mandatory in these cases.
[10:04 PM, 6/8/2026] hu15: That's wonderful. But was bicarb really needed in the DKA patient?
[10:05 PM, 6/8/2026] hu15: Oh I see it has added a clinical note
[10:14 PM, 6/8/2026] hu1: That is what was given to the 23F cited there.
[11:38 PM, 6/8/2026] 42mpa: What I find fascinating here is that the conversation almost immediately moved beyond retrieval.
The search surfaced a real case where bicarbonate appeared. Its use was then immediately questioned.
Awesome sign, great work!
The system surfaced what happened, and the discussion immediately shifted toward clinical reasoning.
That’s exactly the kind of interaction we hope for and speaks well both to the retrieval and to the quality of the discussion that followed. 👏
[12:14 AM, 6/9/2026] hu1: Yes and I set out on a mission on how to make searching better and Claude blew it out of the water in explaining how to setup a semantic search. Very small changes but effects huge.
[1:09 AM, 6/9/2026] 42mpa: That’s awesome! Small technical changes can be massive when they change what becomes retrievable.
The exciting part is that better semantic search doesn’t just improve search. It helps stored journeys become more usable for clinical reasoning.
That’s where continuity, synthesis, and stewardship start becoming much more powerful.
[5:18 PM, 6/9/2026] hu1: Excerpt from claude chats - "Prompt - Right. Let us flip this a bit - You are a mild to moderately educated patient in India, who is interested in this platform and wants to onboard - Severely criticise the idea and along the same lines give ideas on what can be improved to make onboarding the easiest task in the world. We also must make sure the page can be translated to any language a user would want"
Response - Let me step into the shoes of Sunita Devi, 52, a school teacher in Lucknow with Type 2 diabetes and hypertension. Her daughter just showed her this site.
😤 Sunita's brutal review
"Beti, mujhe nahi samajh aa raha is website ka kya use hai. Aur ye sab English mein kyun hai?"
On the landing page:
"Learn from patient narratives" — beta, narrative ka matlab? Kahani? Phir kahani kyun, mujhe ilaj chahiye, story nahi.
"Built on a decade of patient journeys" — journey? Main travel agency par hoon kya?
"Grounded in real evidence" — corporate jargon. Iska matlab kuchh nahi mere liye.
PaJR? Ye kya word hai? Pajamas? Pajeero? Mujhe samajh nahi aaya kya company hai, kya yeh Indian hai bhi.
Sab kuch in English. Hindi nahi, koi language switcher nahi. Mere jaisa middle-aged person kya kare?
Trust signals — completely missing:
No doctor's photo. Who runs this? Real doctor hai ya AI chatbot? Apollo Hospital aisa nahi karte.
"13,000+ patient diaries" — these could be fake numbers. Where's the IMA badge? ICMR approval?
DPDP Act mein deidentified likha hai — but kaun guarantee de raha? No certification logo, no privacy seal.
No Indian phone helpline. No "Made in India" mark. Looks like a Western company.
The search bar:
Animated placeholder showing "Diabetic neuropathy in feet — earliest signs". Neuropathy means what? Mujhe pata hai paer mein jhunjhunaahat hoti hai but ye fancy word kahan se aaya?
No microphone button! I use voice search in WhatsApp every day. Type karna mushkil hai.
Paperclip icon — that means "attach". But why does it say "PRO"? Yeh paisa lagta hai? Hidden charges?
Sign-up modal:
"Save & continue anywhere" — what does anywhere mean? Phone par? Computer par? Confusing.
Email is asked. 70% of my friends don't have email. They have WhatsApp number, that's it.
T&C link goes to a long English page. Nobody will read it. Even my MBA daughter doesn't.
After sign-up — kya hoga? Why am I signing up? The value isn't clear before I commit.
The deal-breaker:
The "Continue on WhatsApp" CTA at bottom is the most important feature for me — but it's the last thing I see. Yeh upar hona chahiye.
No way to "test drive" before sharing my number. I'm not signing up just to see if this even works.
"Beti, ye apps banaane waale Bangalore aur San Francisco mein baithe rehte hain. Hum patients ki real zindagi kabhi samjhe nahi."
[5:20 PM, 6/9/2026] hu1: @hu2 Sir what do you think - "🎯 What needs to change (in priority order)
Tier 1 — Onboarding death-by-1000-cuts
Language switcher visible from second 1 — top of page, globe icon, 10+ Indian languages + Arabic
Voice input mic on the search bar — Web Speech API. Single biggest mobile UX win in India
No sign-up required to try — let users get 2-3 free answers, then offer to save
"WhatsApp number only" path — drop email entirely as primary; email is the secondary path
One sample question that pre-fills + auto-runs — "See it work in 5 seconds" button
Tier 2 — Trust signals
6. Founding doctor's name + photo prominent (Prof Rakesh Biswas) — humanises the platform
7. DPDP Act 2023 / "Anonymised by design" badge with click-to-explain modal
8. Real Indian patient testimonials in their own language with first name only
9. "Made in India · Hyderabad" badge somewhere visible
Tier 3 — Comprehension
10. Replace jargon globally — "narratives" → "stories", "journeys" → "experiences"
11. Larger font option toggle (accessibility — vital for 50+ users)
12. Icon-heavy navigation — fewer English words, more universal symbols
13. "How it works" 20-second animation — visual not textual
Tier 4 — Cultural fit
14. Suggested questions in the user's chosen language (real ones our community asks)
15. Numbers as Indian-style (1,30,000 instead of 130,000)
16. WhatsApp continuation explained upfront — not buried in a footer card"
[6:38 PM, 6/9/2026] hu2: Amazing insights! 👏
[6:43 PM, 6/9/2026] hu15: @hu1 you need to decide very early whether the landing page of the website needs to appeal to the end user or to the VC firm. If we are looking at a VC pitch, then the corporate jargon and English speak are very much essential.
Maybe a different landing page for the end user?
[6:47 PM, 6/9/2026] hu15: The last line is very vital to understand and interpret. Can Claude provide a summary estimate of the probabilities of closing a seed round with the current website and its suggested website 😂
[6:47 PM, 6/9/2026] hu35: You need mentors not VCs. VCs profit at your expense. The smartest businesses delay rushing to VCs.
Rushing to raise institutional money often forces a company to scale before achieving true product-market fit. When you are flush with VC cash, the temptation is to solve operational, product, or strategic problems by throwing money at them (e.g., aggressive marketing, massive hiring).
Mentors push you to optimize the unit economics and find organic traction.
VCs expect you to pour fuel on the fire, even if the engine isn't fully built yet.
[6:50 PM, 6/9/2026] hu15: Absolutely agree, but the tokens are expensive, and till now the website is self funded by @hu1 I guess, which is not a sustainable solution for the long term. Without institutional support or external funding, majority of projects die an untimely death, atleast in India.
[6:51 PM, 6/9/2026] hu35: That is an absolute truth, and in healthcare, the stakes for getting this wrong are incredibly high.
If a healthcare startup prioritizes VC-pleasing buzzwords over direct, empathetic clarity for its primary customers, it doesn't just lose conversions—it loses trust. In healthcare, trust is the foundational currency. Patients or clinicians dealing with health outcomes will immediately bounce if they encounter a wall of clinical-sounding corporate jargon or tech-bro vocabulary.
Furthermore, healthcare has a uniquely complex definition of who the "primary customer" actually is. Unlike standard consumer tech, the person using the product, the person authorizing its use, and the person paying for it are often three entirely different entities.
The messaging architecture must be precisely mapped to whoever holds the key to adoption.
[6:52 PM, 6/9/2026] hu35: Smart health-tech investors are notoriously wary of founders who build for the pitch deck rather than the clinic floor. VCs in this space have burned billions on companies that looked great on paper but failed because doctors refused to adopt the software, or patients found the interface cold and confusing.
When an experienced healthcare VC looks at a landing page that speaks directly, cleanly, and effectively to patients or physicians, it signals something incredibly valuable to them: User Empathy and Product-Market Fit.
By keeping the primary domain completely dedicated to serving, educating, and comforting your primary healthcare customer, you actually build a stronger case for investors than any pitch page ever could. It proves you understand the realities of the healthcare ecosystem.
[6:55 PM, 6/9/2026] hu35: The tech giants and the Government of India have heavily adapted programs specifically for the Indian ecosystem. Because India is one of the fastest-growing AI markets in the world, the competition to get startups locked into specific cloud/API ecosystems is fierce.
If Aditya is building a tech or AI-driven startup in India, here is exactly who provides this support and how to tap into it right now.
## 1. The Global Cloud Giants (India-Specific Tracks)
You do not need US registration or foreign VCs to access these; they have dedicated teams and hubs right here in India.
* *Microsoft for Startups Founders Hub:* This is arguably the most accessible program because *it does not require you to be VC-funded* to start. You can apply at the "Ideate" or "Develop" stage. They offer tiered progression:
* What you get: It starts with $1,000 to $5,000 in Azure credits and can scale up to *$150,000 (roughly ₹1.25 Crore)*.
* The AI Advantage: This includes direct credits for *Azure OpenAI Service*, allowing you to run models like GPT-4o or GPT-4o-mini without paying out of pocket.
* *AWS Activate (via Startup India):* Amazon has a direct partnership with the Government of India's Startup India portal.
* What you get: If you apply directly, you can get $1,000 as a bootstrapped founder. However, if your startup is registered with the DPIIT (Department for Promotion of Industry and Internal Trade), you instantly qualify for *$5,000 to $10,000 in AWS credits*, plus partner offers.
* *Google for Startups Cloud Program:* Google actively courts Indian AI startups through local initiatives like the Google for Startups Accelerator: Appscale (run alongside the Ministry of Electronics and Information Technology - MeitY).
* What you get: Up to $2,000 for pre-funded MVPs, jumping up to *$350,000 over two years* for AI-first startups once you hit the seed stage, covering Gemini and Vertex AI usage.
## 2. Government of India Schemes (Non-Dilutive Capital)
The Indian government has built a robust framework of grants specifically designed to keep early-stage founders from dying an "untimely death" due to infrastructure costs. They take *zero equity*.
* *DPIIT Recognition (The Gatekeeper):* The very first step Aditya should take is registering the entity on the *Startup India portal* to get DPIIT recognition. This unlocks tax holidays, intellectual property fee rebates, and self-compliance modules, but more importantly, it acts as a passport to government funding.
* *Startup India Seed Fund Scheme (SISFS):*
* How it works: Disbursed through selected incubators across India (like IITs, IIMs, and regional tech hubs).
* The Quantum: Up to *₹20 Lakhs* as a pure grant for validation of proof of concept, prototype development, or product trials. Up to *₹50 Lakhs* is available via convertible debentures or debt for market entry and commercialization.
* *MeitY Startup Hub (MSH):* The Ministry of Electronics and IT regularly runs thematic "Challenges" and cohorts for deep-tech and AI startups, offering direct grant money (often ₹5 Lakhs to ₹25 Lakhs) alongside cloud credits.
* *Healthcare Specific: BIRAC (Biotechnology Industry Research Assistance Council):* If this startup touches healthcare, medical devices, or digital health diagnostics, BIRAC is the gold standard in India. Their *BIG (Biotechnology Ignition Grant)* scheme provides up to *₹50 Lakhs* to scientists and entrepreneurs to take an idea closer to commercialization.
## 3. Indian Enterprise & Regional Incubators
If you need immediate institutional sheltering to survive the early token-heavy days, physical and virtual incubation in India provides massive leverage:
* *Institutional Incubators:* Hubs like *CIIE.CO (IIM Ahmedabad), **FITT (IIT Delhi), or **SINE (IIT Bombay)* have direct access to corporate social responsibility (CSR) funds, seed grants, and internal networks that look at product utility rather than VC buzzwords.
* *NASSCOM DeepTech Club:* Getting selected for NASSCOM’s tracks doesn't give you cash directly, but they fast-track your access to enterprise pilots (hospitals, corporate entities) who can become paying customers, which solves the token sustainability problem permanently.
### The Immediate Action Item for the Team
Instead of reshaping the homepage to chase an elusive institutional VC check, the sustainable play for Aditya right now is a two-step checklist:
1. *Incorporate and get DPIIT recognition* via the Startup India portal (takes a couple of weeks).
2. *Apply to the Microsoft for Startups Founders Hub* using the company domain.
This sets up an immediate operational buffer, allowing the product to keep speaking the clean, empathetic language its primary customers need to hear.
[6:56 PM, 6/9/2026] hu15: My experience in the VC world says otherwise, and you don't need to take my word for it. Anyone can google and have a look at the websites of the healthtech firms which have raised at astronomical valuations.
[6:57 PM, 6/9/2026] hu35: To protect your product's focus and manage your infrastructure burn rate, here is the organized directory of institutional programs available for an early-stage deep-tech or healthcare startup in India.
## 1. Global Cloud & AI Infrastructure Credits
These programs are designed to eliminate out-of-pocket token costs without requiring equity or foreign corporate registration.
### Microsoft for Startups Founders Hub
* *The Core Benefit:* Tiered progression providing up to *$150,000 (~₹1.25 Crore)* in Azure cloud credits.
* *The AI Advantage:* Includes direct, dedicated credits for the *Azure OpenAI Service* (enabling access to frontier models like GPT-4o and GPT-4o-mini).
* *Key Eligibility:* Open to pre-seed/bootstrapped teams. You must be privately held, for-profit, operating an original software-based product, and have raised less than a Series C round. You do not need institutional funding to apply.
### Google for Startups Cloud Program
* *The Core Benefit:* Up to $2,000 for early MVP validation, scaling up to *$350,000* over two years once a seed stage or specific growth threshold is reached.
* *The AI Advantage:* Covers infrastructure costs for building on Google Cloud, Gemini API models, and the Vertex AI ecosystem.
### AWS Activate (via Startup India)
* *The Core Benefit:* Standard applications grant $1,000 to bootstrapped founders, but if the company is registered with the Indian Government's DPIIT, it instantly scales to *$5,000 to $10,000* in AWS credits.
## 2. Non-Dilutive Government of India Grants
These are equity-free funding tracks designed to bridge the gap between self-funding and institutional scaling.
### Startup India Seed Fund Scheme (SISFS)
* *The Quantum:* Up to *₹20 Lakhs as a pure grant* for validating proof of concept, prototype development, or product trials. Up to an additional *₹50 Lakhs via debt or convertible debentures* for market entry and commercialization.
* *How it Works:* Disbursed locally through over 300 designated startup incubators across India (such as IIT and IIM entrepreneurship centers).
* *Key Eligibility:* Must be a DPIIT-recognized startup incorporated less than two years ago. The business must have an innovative tech-driven model and an Indian promoter shareholding of at least 51%.
### BIRAC: Biotechnology Ignition Grant (BIG)
* *The Quantum:* *Grant-in-aid up to ₹50 Lakhs* for a maximum operational period of 18 months.
* *Focus Area:* This is the gold standard for healthcare in India. It explicitly supports digital health, medical devices, health diagnostics, and therapeutics.
* *Key Eligibility:* Open to individual entrepreneurs or registered startups/LLPs incorporated less than 5 years ago. The grant covers equipment, cloud/computing infrastructure, team building, and laboratory validation.
### MeitY GENESIS (Gen-Next Support for Innovative Startups)
* *The Quantum:* Part of a large ₹490 Crore scheme run by the Ministry of Electronics and IT specifically targeting deep-tech and electronic innovation.
* *The Core Benefit:* Provides tiered support including *Entrepreneur-in-Residence (EiR) allowances, **Pilot Funding Support* for field-testing your software, and direct deep-tech grants to scale validated systems.
## 3. Institutional Ecosystem Protection
### Tier-1 Academic & Institutional Incubators
* *Who They Are:* Hubs like *FITT (IIT Delhi), **CIIE.CO (IIM Ahmedabad), and **SINE (IIT Bombay)*.
* *The Core Benefit:* They provide access to corporate social responsibility (CSR) grant funding, low-cost institutional infrastructure, legal and data-compliance guidance (essential for navigating India's DPDP Act and healthcare regulatory standards), and soft landing networks.
## The Immediate Operational Roadmap
To stop spending personal capital on token pipelines, a simple sequence is recommended:
[ Domain & Basic MVP Ready]
│
▼
[ Step 1: Apply to Microsoft Founders Hub] ───► Immediate access to Azure OpenAI Credits
│
▼
[ Step 2: Register on Startup India Portal] ──► Unlocks DPIIT Certificate
│
▼
[ Step 3: Apply to SISFS or BIRAC BIG] ───────► Secures ₹20L to ₹50L Equity-Free Cash
This sequence builds an immediate infrastructure buffer via Microsoft while setting up the corporate scaffolding to pull in non-dilutive government capital.
[7:00 PM, 6/9/2026] hu35: The short answer is *no, not usually at the earliest stages—and this is where the disconnect between the *public-facing website and the internal reality of the fund becomes most apparent.
There is a distinct timeline shift in how Indian VCs operate. While a Series C or growth-stage investor looks at a polished, enterprise-ready domain and matches it against a massive valuation, *early-stage Indian VCs operate on a completely different psychological wavelength.*
### The Reality of Early-Stage Indian VCs (Seed to Series A)
If you approach a prominent Indian seed-stage fund (like Blume Ventures, India Quotient, or Elevation Capital) with nothing but high-level "corporate speak" and astronomical valuation demands on day one, it is often an immediate red flag. Here is why:
#### 1. The Frugality Filter (Skepticism of Pre-Product Burn)
Indian VCs are notoriously pragmatic. They know the domestic market is highly price-sensitive, and they have seen billions of dollars wasted on over-capitalized startups that burned cash on "looking big" before finding product-market fit.
* If an early-stage founder presents a hyper-corporate, heavily jargonized facade without showing deep, grassroots understanding of the Indian consumer, clinician, or hospital administrator, the VC smells *inflated overheads* and *premature scaling*.
#### 2. The Focus on Unit Economics and Margin
Unlike the US market, where enterprise SaaS can easily command 80% to 90% gross margins, the Indian healthcare ecosystem forces startups to deal with heavy operational complexities (on-the-ground sales, low digital infrastructure penetration in Tier-2/3 cities, and tight medical budgets).
* Early-stage Indian VCs want to see how you are going to survive the "token burn" or distribution costs organically. They prioritize a lean, highly efficient architecture over a glossy corporate presentation.
#### 3. "Show, Don't Spell Out"
At the seed stage, an Indian VC values a founder who has hacked together an MVP, validated it with 10 local doctors or 500 patients, and can explain the unit economics on the back of a napkin. If the landing page looks like a multinational health conglomerate but the actual product lacks a repeatable retention loop, the deal falls apart during due diligence.
### The Evolution: When the Flip Happens
The astronomical valuations and heavy corporate branding you see on Google are the result of an *evolutionary flip*. A startup's messaging shifts dramatically as it scales through the funding ecosystem:
[ Seed / Pre-Seed ] ───────► [ Series A / B ] ───────────► [ Series C+ / Growth ]
Focus: Bootstrapping Focus: Market Traction Focus: Platform Scale
Tone: Core Utility Tone: Institutional Quality Tone: Enterprise Category Leader
Target: The End User Target: The Enterprise Buyer Target: Global Capital & LPs
1. *The Early Phase (The "Utility" Stage):* You build for the user. You survive on lean operations, government grants (like BIRAC BIG or SISFS), and cloud credits. Your website is a tool, not a billboard for investors. VCs back you because of your *traction* and *founder-market fit*.
2. *The Growth Phase (The "Institutional" Stage):* As you raise larger rounds (Series B/C) to sell to major enterprise healthcare chains, corporate hospital networks, or international clients, your primary customer becomes an enterprise buyer. Now, the website flips to the corporate dialect because it matches the scale of the contracts you are signing.
### The Bottom Line for hu1
Chasing the corporate look of a unicorn healthcare firm before securing the underlying unit economics is putting the cart before the horse.
The smartest play for an early-stage Indian startup is to *keep the main site hyper-focused on solving the primary customer's immediate pain point* in plain, undeniable language. When pitching an Indian VC, let your pitch deck, your data room, and your separate investor URL do the heavy lifting of showing how that simple tool scales into a massive, multi-million dollar asset class.
For a deeper dive into the exact framework professional investors use to analyze digital health tools, check out this discussion on What VCs Look for in HealthTech Startups. This resource is highly relevant because a seasoned healthcare venture expert breaks down the critical balance between clinical utility, workflow alignment, and investor-scale metrics within early-stage innovation.
[7:00 PM, 6/9/2026] hu35: You are looking at late stage financing
[7:57 PM, 6/9/2026] hu36: Hi everyone,
Had got busy elsewhere and couldn't track messages.
I guess you are planning to make this into a product-service.
We need to be upfront ans transparent about our sustainability model.
For example not for profit, running on donations.
Or
Not for profit but will charge user fee
Or for profit through subscriptions
Etc.
[8:17 PM, 6/9/2026] hu12: JMIR Publications invites submissions to a new section titled "Waste in Research" in its open access journal JMIR Metascience and Research Integrity. This new journal focuses on publishing metascience (also known as metaresearch or "research on "research"), which aims to increase the quality and efficiency of research and advance the quality, transparency, and integrity of the scholarly publishing ecosystem. The journal addresses ethical challenges, best practices, and scientific integrity issues through metascience and evidence-based research standards.
group invite: https://chat.whatsapp.com/Hbe2YNqlGie33qyesvcn5A
Read the Full Call for Papers Here: https://metascience.jmir.org/announcements/682?utm_campaign=Call%20for%20Papers
[8:38 PM, 6/9/2026] 42mpa: What I like about this framework is that it attacks friction directly.
Language, voice input, WhatsApp onboarding, immediate utility, and trust signals all lower the activation energy required for participation. That matters because if the patient never gets through the front door, none of the deeper architecture has a chance to work.
I also do not see the different perspectives here as competing.
hu1 is focused on reducing friction and onboarding. hu35 is focused on sustainability. hu15 is focused on market realities. All three layers seem important.
What I find encouraging in hu35’s observations is that many of the infrastructure barriers that might have made this impossible a few years ago appear substantially lower today. Between cloud credits, startup programs, incubators, and government-supported innovation pathways, there may be more opportunities than ever to experiment with continuity-focused infrastructure without needing to build the entire vision at once.
That makes me think the limiting factor may be less about technology and more about preserving a clear architectural north star for what continuity should eventually become.
The question I keep coming back to is what happens after onboarding succeeds.
The current discussion is largely about entry. My question is about continuity.
If a patient arrives through voice input, WhatsApp, a simplified landing page, or eventually a dedicated app, what is the primary unit being preserved?
A conversation? A question? An answer? Or a journey?
From my perspective, one of the most interesting things about PaJR is that it has never really been about data collection alone. Its unique strength is longitudinal continuity.
If the experience becomes “ask AI a health question,” it enters a very crowded landscape. Google, ChatGPT, Claude, and countless health bots already provide answers.
PaJR has an opportunity to answer a different question:
“What has been happening to this person over time?”
That feels fundamentally different.
Most systems are optimized to collect observations. Far fewer are designed to recognize trajectories.
An isolated observation may be interesting. A trajectory changes meaning.
The same symptom, laboratory value, medication change, imaging finding, or life event can mean something entirely different when viewed as part of an evolving pattern rather than a single moment in time.
That is why I keep returning to continuity.
The easier we make onboarding, the more important continuity becomes. Successful onboarding creates more observations. Continuity determines whether those observations eventually become understanding.
In that sense, I do not see WhatsApp and a future app environment as competing ideas. I see them as potentially serving different functions.
WhatsApp may be the easiest local onboarding path. It has obvious strengths: low cost, rapid adoption, community, conversation, and easy onboarding.
But an app may be the most scalable global continuity path.
A dedicated app environment may ultimately be where continuity lives: timelines, events, labs, medications, uploads, follow-up tracking, structured chronology, anonymization, and longitudinal case development.
The average person in India, the U.S., Europe, Africa, or South America may not understand PaJR groups, case sharing workflows, collaborative cognition, or participatory medicine.
But they understand:
Download app.
Create account.
Enter information.
Come back later.
That is already a learned behavior globally.
So maybe the pathway is phased.
Phase 1: WhatsApp/chat for low-friction entry, trust, community, and early capture.
Phase 2: a lightweight app for structured continuity, timelines, events, uploads, medication changes, symptom tracking, basic AI-generated chronology, and follow-up reminders.
Phase 3: a knowledge layer for anonymized review, trajectory recognition, pattern detection, case synthesis, research generation, and observability at scale.
The strategic question may not be whether we need an app immediately. It may be where continuity ultimately lives.
Part of why I keep returning to this question is that I have been sketching what a patient-side continuity architecture might look like over time. The details are less important than the underlying principle: a patient should ideally build their case once and then maintain it as it evolves, rather than repeatedly reconstructing it across encounters, platforms, and systems.
Because the deeper problem in medicine is often not that data does not exist.
It is that the data does not stay connected long enough for the case to fully form.
Symptoms live in one place. Labs live somewhere else. Imaging sits elsewhere. Medication changes become disconnected from outcomes. Patient narrative becomes separated from clinical narrative.
The case fragments.
PaJR already captures signal remarkably well.
The opportunity may be to become equally good at holding that signal long enough for trajectories to emerge.
In Lucerna language, perhaps the question becomes:
How do we hold the signal long enough for recognition to occur?
Because capture is not continuity.
And continuity is what allows observations to become trajectories.
[8.43 pm, 09/06/2026] hu2: 👏
[8:44 PM, 6/9/2026] 42mpa: I think this is exactly the right question.
To me, the sustainability model has to be transparent from the beginning, especially because the patient should not become the financial burden of the system.
The cases are the foundation. They should not become the cost.
Longer term, if PaJR becomes a structured clinical knowledge network, the value created may be greatest for research, institutions, education, and clinical insight.
So the model I keep imagining is something like:
patients contribute experience
the system creates structure
institutions that benefit from that structure help support and fund it
Not as extraction from patients, but as reinvestment into the network itself.
That is also why a dedicated platform matters. It does not just improve usability. It creates a shared, trusted environment with consent, privacy, anonymization, clearer roles, and safer collaboration between patients, advocates, clinicians, and researchers.
Ideally, the sustainability model protects the humanitarian purpose while allowing the infrastructure to survive.
[8:48 PM, 6/9/2026] hu35: In my view a sustainable model first and foremost preserves the dignity of patients and shares with them equitable any gains made by a for-profit enterprise or value created by a not for profit enterprise.
[8:52 PM, 6/9/2026] hu35: This is a profound and highly ethical foundation for designing a Patient Journey Record (PaJR). I am shifting the paradigm from treating patient data as a mere commodity to treating the patient as an active, dignified stakeholder—both ethically and economically.
In the emerging landscape of healthcare technology, framing sustainability around dignity and equity directly addresses the historical power asymmetry between data creators (patients) and data processors (enterprises).
Here is a breakdown of how this philosophy can be translated into structural architecture, particularly when aligning with strict data protection principles like those in the Digital Personal Data Protection (DPDP) Act:
1. Preserving Dignity: The Patient as the Sole "Data Principal"
Dignity in a digital healthcare ecosystem is entirely about agency, autonomy, and trust.
* Absolute Ownership: The patient is the absolute Data Principal. The PaJR platform, hospitals, and doctors are merely custodians or "Data Fiduciaries."
* Granular, Dynamic Consent: Dignity means the patient chooses not just if their data is shared, but which specific parts (e.g., sharing orthopedic history for research but keeping mental health or reproductive data private) and for how long. Consent should be as easy to revoke as it is to give.
* Uncompromised Erasure (The Right to be Forgotten): A dignified model ensures that if a patient decides to exit the ecosystem, their digital footprint can be completely wiped or anonymized, ensuring they retain ultimate control over their medical narrative.
2. Equitable Benefit-Sharing in a For-Profit Model
If a commercial enterprise generates value, insights, or profits from aggregated, anonymized patient journeys (such as training specialized medical LLMs, refining diagnostic tools, or accelerating clinical trials), the patient must not be left out of the economic equation.
* Data Dividends / Micro-Payouts: Utilizing secure, decentralized tracking to distribute micro-rewards or dividends directly to patients when their anonymized records contribute to a commercial breakthrough or a funded research study.
* Subsidized Care Services: Instead of direct cash, gains can be redirected to lower the patient's personal healthcare costs—providing them with free premium AI diagnostics, subsidized consultations, or heavily discounted chronic disease management tools within the PaJR ecosystem.
* The "Data Union" Concept: Aggregating patient data in a collective framework where the platform negotiates on behalf of the patients, ensuring that pharmaceutical or tech companies pay a fair, equitable price that directly benefits the collective pool of Data Principals.
3. Value-Sharing in a Not-For-Profit Model
For a non-profit or public good enterprise, the "gains" are measured in societal value, improved community health outcomes, and open-source medical knowledge. Equitable sharing here looks different but is equally impactful:
* Democratic Data Governance: Giving patients a seat at the table in deciding what research questions the non-profit pursues using the longitudinal data.
* Public Health Repositories: Ensuring that any insights derived from the PaJR are non-proprietary and feed back into the public health ecosystem, directly improving treatment protocols at the primary healthcare level for the community.
* Personalized Predictive Insights: Returning the collective value directly to the individual. For instance, if the non-profit discovers a new disease progression pathway by analyzing thousands of journeys, the PaJR uses that insight to send a personalized, predictive health alert to the patient, preventing future complications.
> The Core Realization: A longitudinal patient journey is not just a static file of PDFs and lab reports; it is a living, evolving story of human life. By embedding dignity and equity into the core code of the PaJR, you build an inherently self-sustaining ecosystem. Patients will willingly share their data because they know they are respected partners, not products.
[9:02 PM, 6/9/2026] 42mpa: One additional thought that keeps pulling at me.
I do not think the long-term opportunity for PaJR is necessarily to replace every health tool people already use. Most people already have pieces of their story scattered across multiple systems. One tool captures symptoms, another captures activity, another captures sleep, medications, nutrition, wearable data, laboratory values, or clinical notes.
Each of those streams contains information.
The problem is that people do not experience their lives as separate streams. They experience them as journeys.
That is why I keep coming back to continuity. The opportunity may be less about replacing existing tools and more about creating a place where those fragments can converge without losing their identity.
To me, the value of continuity is not simply memory. It is the ability to transform fragments into trajectories and trajectories into understanding.
In that sense, the goal is not to own every data stream. The goal is to create a continuity architecture capable of integrating them. People should be able to continue using the tools that already work for them while allowing those observations to contribute to a larger longitudinal picture.
Perhaps another way to think about it is that continuity functions less like a collection of records and more like a living river. Not because every tributary becomes the same thing, but because their relationship to one another becomes visible.
That is where I think continuity becomes powerful. Most systems are already very good at collecting observations. Far fewer are designed to recognize trajectories.
An isolated observation may be interesting. A trajectory changes meaning.
The same symptom, laboratory value, medication change, imaging finding, or life event can mean something entirely different when viewed as part of an evolving pattern rather than a single moment in time.
That is also why I do not necessarily see WhatsApp and a future app environment as competing ideas.
WhatsApp may be an excellent entry point because it lowers friction, builds trust, creates community, and allows rapid onboarding.
A dedicated app, on the other hand, may ultimately become the place where continuity lives. Timelines, events, uploads, medication changes, follow-up tracking, structured chronology, consent, privacy controls, anonymization, and longitudinal case development all become easier when they exist within a shared and trusted environment.
The app does not replace the conversation. It gives the conversation somewhere to mature into continuity.
In that sense, the long-term opportunity may not be to replace existing tools at all, but to become the continuity layer that sits above them, helping people build their case once and then maintain it as it evolves rather than repeatedly reconstructing it across encounters, platforms, and systems.
The more I think about it, the more it feels like onboarding and continuity are two halves of the same problem.
The front door gets people in.
Continuity gives them a reason to stay.
Ultimately, I keep wondering whether the unique opportunity for PaJR is not simply to become another health tool, but to become the place that helps people understand what has been happening to them over time.
Not replacing the tributaries.
Helping people understand the river.
[9:06 PM, 6/9/2026] hu35: Proposal for a Patient Journey Record (PaJR) Commons:
A Patient-Led, Community-Stewarded, Clinically-Governed Architecture for Longitudinal Health and Genomic Data
Executive Summary
Healthcare increasingly generates longitudinal data that extend far beyond episodic encounters. Clinical records, patient narratives, wearable data, imaging, laboratory results, and genomic information together form a continuously evolving representation of a person’s health journey.
Current digital health systems often fragment this journey across institutions while simultaneously creating asymmetries in value, governance, and trust. Patients contribute data but rarely participate in decisions regarding its stewardship or in the benefits generated from its secondary use.
This proposal introduces the Patient Journey Record (PaJR) Commons, a patient-led, community-stewarded, and clinically-governed architecture designed to preserve dignity, strengthen trust, enable responsible innovation, and ensure equitable benefit-sharing.
Rather than treating health information as a commodity to be owned and traded, the PaJR Commons treats health and genomic data as a shared societal resource requiring fiduciary stewardship and reciprocal responsibility.
Foundational Principles
The PaJR Commons rests on seven principles:
1. Patient Dignity
Individuals remain the primary subjects of their own journeys and retain meaningful rights over participation and consent.
1. Stewardship Rather Than Ownership
Health and genomic information are not treated as transferable property. Instead, authorized institutions act as fiduciary stewards.
1. Reciprocity
Those who contribute to collective knowledge should share in the benefits generated from that knowledge.
1. Solidarity
Benefits should strengthen communities and health systems, not merely reward individuals.
1. Privacy by Design
Protection mechanisms should be embedded into the architecture itself rather than added retrospectively.
1. Clinical Integrity
Healthcare professionals remain essential interpreters and custodians of meaning.
1. Public Good
The system should advance research, equity, and societal wellbeing.
⸻
1. Governance Architecture
2.1 Health Data Stewardship Trust
The PaJR Commons is governed through an independent Health Data Stewardship Trust.
Its functions include:
* protecting patient interests;
* evaluating secondary-use requests;
* negotiating research agreements;
* ensuring transparency;
* overseeing benefit-sharing mechanisms;
* maintaining ethical standards.
The Trust does not own patient data.
Instead, participants authorize the Trust to act as a fiduciary steward on behalf of the community.
⸻
2.2 Multi-Stakeholder Governance
Governance should include representation from:
Patients and citizen groups.
Clinicians and health professionals.
Bioethicists.
Data protection experts.
Public health authorities.
Community representatives.
Rare disease and genomic advocacy groups.
⸻
2.3 Independent Ethics and Access Committee
Every secondary-use proposal should undergo review for:
* scientific merit;
* social value;
* equity implications;
* privacy risks;
* conflicts of interest.
Human oversight remains central.
⸻
1. Legal Framework
The architecture should comply fully with the Digital Personal Data Protection Act 2023.
Key principles include:
Explicit informed consent.
Purpose limitation.
Data minimization.
Accountability of designated Data Fiduciaries.
Withdrawal mechanisms.
Reasonable security safeguards.
The legal relationship should be framed as:
authorized stewardship rather than transfer of rights.
1. Dynamic Consent Architecture
Consent should be granular and purpose-specific.
Examples include:
Clinical care.
Public health functions.
Academic research.
AI model development.
Pharmaceutical research.
Genomic studies.
Participants should be able to:
* review permissions;
* modify preferences;
* withdraw future participation;
* receive understandable explanations.
Consent should be treated as a continuing relationship rather than a one-time event.
⸻
1. Technical Architecture
The system should remain technology-neutral.
Possible components include:
Encryption.
Role-based access controls.
Audit trails.
Tokenization of identifiers.
Differential privacy.
Secure research environments.
Federated analytics where appropriate.
Privacy-enhancing technologies.
No single technology should be mandatory.
The architecture should prioritize simplicity, interoperability, and maintainability.
⸻
1. Longitudinal Narrative Preservation
A Patient Journey Record is more than structured data.
It includes:
* symptoms;
* experiences;
* preferences;
* family context;
* social determinants;
* treatment responses.
These narratives provide meaning and continuity and should be preserved while applying robust de-identification procedures.
⸻
1. Genomic Data Governance
Genomic information requires enhanced protections because it is:
* highly identifying;
* persistent;
* familial;
* intergenerational.
Accordingly:
Genomic data should be regarded as privacy-protected rather than truly anonymous.
Additional ethics review should be mandatory.
Policies for incidental findings should be established.
Genetic counseling pathways should be available.
Family implications should be explicitly acknowledged.
International transfer safeguards should be defined.
⸻
1. Professional Stewardship
Clinicians remain essential participants.
Professional stewardship councils should oversee:
* data quality;
* interpretation standards;
* clinical relevance;
* contextual accuracy.
The PaJR Commons is intended to strengthen—not replace—the therapeutic relationship.
⸻
1. Benefit-Sharing Framework
Value generated from secondary use should be distributed through collective mechanisms.
Examples include:
Community screening programs.
Genetic counseling services.
Rare disease support programs.
Subsidized diagnostics.
Digital infrastructure.
Training of community health workers.
Public health initiatives.
Individual service credits may also be considered where appropriate.
The emphasis should remain on solidarity rather than commodification.
⸻
1. Liability and Accountability
Responsibilities must be clearly defined.
This includes:
Data Fiduciaries.
Data Processors.
Participating institutions.
Technology providers.
Cybersecurity obligations.
Breach notification mechanisms.
Independent audits.
⸻
1. Transparency and Public Trust
The Commons should publish annual reports describing:
* approved studies;
* denied requests;
* benefit-sharing outcomes;
* cybersecurity incidents;
* financial statements;
* governance activities.
Transparency should be considered a core trust mechanism.
⸻
1. International Alignment
The PaJR Commons should align with emerging international practices including:
* Genomics England;
* OpenSAFELY;
* GA4GH frameworks;
* Indigenous Data Sovereignty principles;
* responsible AI guidelines.
⸻
Strategic Vision
The PaJR Commons seeks to transform fragmented health information into a trusted, longitudinal, learning ecosystem.
Its purpose is not to create a marketplace for health data.
Its purpose is to create a durable social contract between patients, professionals, researchers, and society.
In this model, trust becomes the primary infrastructure.
Health and genomic information are understood not as commodities to be extracted, but as shared knowledge resources whose stewardship carries obligations of dignity, reciprocity, solidarity, and public responsibility.
Proposed Definition
The Patient Journey Record Commons is a patient-led, community-stewarded, clinically-governed and privacy-preserving ecosystem for longitudinal health and genomic information that advances care, research, and public good through fiduciary trust and equitable benefit-sharing.
[9:24 PM, 6/9/2026] 42mpa: What stands out to me here is the shift from treating patient data as an asset to treating the patient as a stakeholder.
If journeys become the foundation of the system, then consent, continuity, ownership, and stewardship stop being technical features and become constitutional principles.
I also think the idea of the patient as the Data Principal changes how we think about participation. People are often asked to contribute information, but far less often invited to participate in the value that information creates.
Whether the model is for-profit or not-for-profit, the underlying principle feels similar: the patient remains a partner rather than a product.
What I find particularly compelling is your observation that a patient journey is not simply a collection of records, reports, and PDFs. It is a living story unfolding across time.
If that is true, then dignity is not just about privacy. It is also about preserving agency over that story, how it is shared, how it is stewarded, and how any value generated from it ultimately serves the people who made that knowledge possible in the first place.
That feels like a very different foundation from many existing health data models.
[9:45 PM, 6/9/2026] hu1: End user. I'm very clear on this.
[9:46 PM, 6/9/2026] hu1: I think we are still quite a while away from that. Maybe end of this year or early next year.
[9:48 PM, 6/9/2026] hu2: 2014👇
[9:49 PM, 6/9/2026] hu1: I still think we are at least 5 to 10k proper patients away from actually seeing how this evolves. Until then it is purely speculative on its USPs
[9:50 PM, 6/9/2026] hu15: 5-10k patients😳😳😳
[9:50 PM, 6/9/2026] 42mpa: This is a very strong governance framing.
What stands out to me most is the shift from treating patient data as an asset to treating the patient as a stakeholder within a governed commons. The line that feels especially important is that “trust becomes the primary infrastructure.”
That seems central. If patients are going to contribute longitudinal journeys, especially narratives, genomic context, family history, and lived experience, then trust cannot be an afterthought. Consent, dignity, reciprocity, transparency, and benefit-sharing have to be built into the architecture from the beginning.
I also like the distinction between ownership and stewardship. It feels more appropriate for longitudinal health data because the journey is not simply a transferable object. It is a living record of a person’s experience over time.
The bridge I keep thinking about is between governance, continuity, and the learning ecosystem Rakesh has been pointing toward. A Commons can protect, govern, and steward the data, but the underlying PaJR still has to preserve the coherence of the journey itself. Otherwise, we risk building an ethical governance structure around fragments.
So perhaps the architecture has three inseparable layers.
Continuity architecture: how the patient journey remains connected over time.
Governance architecture: how that journey is protected, stewarded, shared, and used responsibly.
Learning ecosystem architecture: how coherent journeys generate insight that improves care, research, education, and public health.
To me, those layers strengthen each other. Continuity makes the journey meaningful. Governance makes the journey trustworthy. The learning ecosystem makes the journey generative.
What becomes especially interesting at scale is that the Commons begins to function as more than a repository of records. Imagine not thousands of isolated documents, but millions of longitudinal journeys. Not disconnected observations, isolated diagnoses, or single encounters, but trajectories.
At that point, entirely new questions become possible. What patterns tend to precede diagnostic delay? What trajectories predict treatment response? Where do follow-up failures occur? Which care pathways produce the best outcomes? What combinations of symptoms, genetics, environment, treatment decisions, and lived experience tend to converge over time?
Those are difficult questions to answer within fragmented systems because the continuity required to observe the full trajectory rarely survives. That is why I continue to think continuity is so important.
Without continuity, we have data. With continuity, we have trajectories. With enough trajectories, we begin to generate knowledge. With enough knowledge, we create opportunities for research, education, improved care pathways, public health insight, and responsible innovation.
In that sense, the Commons becomes more than a governance structure. It becomes a learning ecosystem.
The question then becomes: who benefits from the value that ecosystem creates?
Historically, the answer has often been institutions alone. What I find compelling about this proposal is that it points toward a different model: patients contribute journeys, PaJR creates continuity, researchers and institutions generate insight, value flows back into the Commons, the Commons strengthens the ecosystem, and patients and communities benefit.
That is where the benefit-sharing model becomes especially powerful. The value created could flow back through subsidized diagnostics, patient support, genetic counseling, clinical education, community health programs, or infrastructure that helps more patients participate.
That transforms the model from extraction into reinvestment.
Ultimately, this moves PaJR beyond a health app, data repository, or case archive. It points toward a patient-centered longitudinal knowledge ecosystem grounded in dignity, stewardship, public good, and reciprocal value. The result is not simply a better database. It is a self-reinforcing system in which continuity, trust, knowledge generation, and public good strengthen one another over time.
[9:51 PM, 6/9/2026] hu1: Yes sir. Frankly, I try to put myself in the patient's boots and we offer very little of value. Sorry I'm very harsh on myself.
[9:52 PM, 6/9/2026] hu15: To the patient, yes. But as a knowledge base, immense
[9:53 PM, 6/9/2026] hu16: That's why I feel @42mpa's point is valid. Institutions specially those working on developing frontier clinical LLMs will derive immense value from PaJR
[9:54 PM, 6/9/2026] hu35: At said and done, if all stakeholders are happy and feel appreciated and cared for the endeavour would have left in its wake love, compassion and meaningful service.
[9:54 PM, 6/9/2026] hu1: To the patient, yes. But as a knowledge base, immense
Not sure about the latter either. A patient advicate on probing told me that his patient has started developing Proximal muscle weakness while the PaJR is about him autopiloting images of BP readings and tablets.
That too me is failure in broad daylight.
[9:54 PM, 6/9/2026] hu1: Yes absolutely and that value will come after 5k real longitudinal journeys. Most patients I see have now become autopilots themselves.
[9:55 PM, 6/9/2026] hu15: Yes they won't share on PaJR because they don't feel they are getting treated here. As you said we had pivoted to food plate sharing and activity logs. We need to treat
[9:56 PM, 6/9/2026] hu35: Human Purpose and Moral Foundation
The ultimate success of the Patient Journey Record Commons will not be measured solely by the number of records collected, research studies enabled, or technologies deployed.
Its success will be measured by whether patients, families, clinicians, researchers, communities, and institutions feel respected, valued, and cared for through their participation.
Healthcare is fundamentally a human enterprise. Data, algorithms, governance structures, and legal frameworks are only instruments in service of that larger purpose.
If designed well, the PaJR Commons can create a virtuous cycle in which:
* patients experience dignity and trust;
* clinicians experience meaning and professional fulfilment;
* researchers experience responsi* ble access to knowledge;
* communities experience tangible benefits;
* institutions experience legitimacy and public confidence.
When all stakeholders feel appreciated and cared for, the enduring legacy of the endeavour will not merely be better data or better technology.
Its legacy will be the strengthening of relationships and the cultivation of trust.
Ultimately, the PaJR Commons aspires to leave in its wake something far more valuable than information:
love expressed through compassion, compassion expressed through service, and service expressed through shared responsibility for one another’s wellbeing.
In this sense, the PaJR Commons is not simply a technical infrastructure.
It is a social covenant grounded in dignity, reciprocity, solidarity, and care.
[10:00 PM, 6/9/2026] hu1: Reading between the lines here - I think the very reason why the current Healthcare mess came to be is because self-empowerment and accountability are very low among patients/people in general. Most people live autopilot - the west has taught me this lesson coldly and that needs to be broken. Nearly all healthcare systems are designed for such people. Which is why tablets/medicines have become the be all end all of medicine
No wonder, even parallely governments world over have become more authoritarian because these are the same patients who also morph into citizens.
[10:00 PM, 6/9/2026] 42mpa: I think that is a fair point. We probably do need enough real patients to see what PaJR actually becomes in practice rather than assuming the USP too early.
At the same time, 5–10k patients feels less like the destination and more like an early validation threshold.
For context, some single-stream health platforms have reached enormous scale. MyFitnessPal has been reported at more than 280 million users, Strava more than 180 million users, and Fitbit has historically had well over 100 million registered users.
The interesting thing is that none of those platforms are really trying to solve the same problem.
Most health tools are built around a single stream of information. One captures nutrition. Another captures activity. Another captures sleep. Another captures wearables. Another captures medications. Another captures glucose. Another captures clinical records.
Each stream contains information.
The problem is that people do not experience their lives as separate streams.
They experience them as journeys.
That is why I keep coming back to continuity.
The opportunity for PaJR may not be to replace those tools at all. It may be to become the continuity layer that sits above them.
In other words, the goal is not necessarily to own every data stream. The goal is to help people understand the relationship between them.
People should be able to continue using the tools that already work for them while allowing those observations to contribute to a larger longitudinal picture.
Perhaps another way to think about it is that most health tools function like tributaries.
Each carries part of the story.
The value of PaJR may be in helping people understand the river.
Not because every tributary becomes the same thing, but because their relationship to one another becomes visible over time.
That is also where I see the learning ecosystem becoming especially powerful.
Without continuity, we have data.
With continuity, we have trajectories.
With enough trajectories, we begin to generate knowledge.
At that point the value extends far beyond individual case management. Researchers can begin asking questions that are very difficult to answer today: what patterns precede diagnostic delay, what trajectories predict treatment response, where follow-up failures occur, which pathways produce the best outcomes, and how symptoms, genetics, environment, treatments, and lived experience interact over time.
That is where PaJR starts looking less like another health app and more like a longitudinal learning ecosystem.
So I agree that 5–10k patients may be enough to discover the real USP.
What excites me is the possibility that if the continuity architecture is right, the eventual opportunity may be far larger than any single tool because it is not competing with the tributaries.
It is helping people understand the river.
[10:01 PM, 6/9/2026] hu1: Any product released into this ecosystem will suffer from the same autopilot syndrome.
[10:14 PM, 6/9/2026] hu15: It will. How to ensure that the patient takes ownership?
[10:30 PM, 6/9/2026] hu1: My hunch is it is neither money nor outcomes!
[10:33 PM, 6/9/2026] 42mpa: I think hu1’s concern and hu15’s question are actually pointing to the same challenge from two different directions.
If patients only contribute experience so that researchers, institutions, or AI systems benefit later, then the model risks becoming valuable to everyone except the person whose journey made the knowledge possible.
At the same time, patient ownership cannot simply be demanded. It has to be designed for.
If the system asks patients to “take ownership” but gives them no structure, no feedback, no visible continuity, and no sense that their participation changes anything, many people will naturally drift into autopilot. That is not simply a patient problem. It is also a design problem.
So I think the patient has to experience value during participation itself.
They should experience clearer continuity, a better organized history, visible follow-up gaps, structured questions, safer sharing, and a sense that their journey is being held rather than lost.
Ownership grows when participation becomes meaningful.
That is why I keep coming back to continuity. Continuity is not simply record keeping. It is the mechanism that allows a patient to see their own journey unfolding over time.
Then the larger knowledge value can develop from that foundation.
At scale, the same continuity architecture that helps an individual patient today can also generate research value, clinical learning, better models, public health insight, and institutional value tomorrow.
If enough coherent longitudinal journeys accumulate, PaJR becomes more than a repository of patient stories or records. It becomes a learning ecosystem.
Researchers, universities, public health organizations, health systems, and potentially even industry partners working on diagnostics, therapeutics, clinical AI, or care delivery could derive substantial value from that kind of longitudinal knowledge.
But the key is that this value should not leave the ecosystem permanently.
It should flow back into the Commons.
Patients contribute journeys.
PaJR preserves continuity.
Coherent journeys generate knowledge.
Researchers and institutions generate insight.
Value flows back into the Commons.
The Commons strengthens care, participation, education, infrastructure, and research.
That creates a very different relationship than traditional data models because the people who make the knowledge possible remain connected to the benefits generated from it.
Over time, that reinvestment could support stronger infrastructure, patient advocates, care navigators, genetic counseling services, clinician education, rare disease programs, community health initiatives, subsidized diagnostics, and support for patients in health-disparity regions who otherwise struggle to access care.
If the ecosystem became large enough, it could even help create patient-support funds or navigation support for people who need testing, labs, specialist access, or help being shepherded through fragmented systems.
That is what keeps the model from becoming extractive.
The patient receives value now through continuity, structure, and support.
The research ecosystem receives value later through coherent longitudinal journeys.
And the value generated from that research returns to strengthen the Commons.
To me, that feels like the bridge between patient ownership, patient care, research, sustainability, and public good.
It also protects the moral foundation Guriqbal described: love, compassion, service, and shared responsibility. The point is not simply to collect more information. The point is to build a system where patient experience becomes knowledge, knowledge improves care, and the benefits of that learning return to the patients and communities who made it possible.
[10:55 PM, 6/9/2026] 42mpa: One thing that keeps striking me is that what is emerging here feels larger than any individual feature, app, governance structure, or research initiative.
The potentially transformative part is the combination of several ideas that are rarely brought together in the same architecture:
* longitudinal continuity as a first-class object;
* patient-centered observability;
* stewardship rather than extraction;
* learning through trajectories rather than isolated encounters;
* value flowing back into the communities that generate the knowledge.
Most health systems today are organized around encounters.
Much of what is being described here is organized around journeys.
That is a fundamentally different center of gravity.
As medicine increasingly moves toward chronic disease, multimorbidity, rare disease, genomics, precision medicine, patient-generated data, wearables, and AI-assisted care, continuity becomes more important rather than less important.
Because all of those things become harder to understand when they are fragmented.
What makes this especially interesting is that the problem is not unique to any one country, healthcare system, or disease category. Fragmentation is a global problem. Diagnostic delay is a global problem. Loss of continuity is a global problem.
A system capable of preserving journeys, learning from trajectories, and returning value to the communities that generate that knowledge could potentially improve not only individual care, but also how clinical knowledge itself is produced, shared, stewarded, and applied across populations.
Perhaps the deeper opportunity is not simply building a better health tool.
It is creating an architecture in which human experience can remain coherent long enough to become recognizable, learnable, and ultimately useful for improving care.
In that sense, continuity, governance, and the learning ecosystem are not separate problems.
They are three dimensions of the same one.
[12:56 AM, 6/10/2026] hu10: Patients must "feel" the value and that is inbuilt in Rehabilitation Medicine perhaps. FIM being a simplest form there are many QoL scales essential to show the feel as mirrorin front of the patient
[1:12 AM, 6/10/2026] hu7: https://classworkdecjan.blogspot.com/2026/06/denoised-evidence-in-clinical-trials.html?m=1
[1:17 AM, 6/10/2026] hu1: How do we transfer this the PaJR platform sir? Certainly a great idea
[1:20 AM, 6/10/2026] hu10: Once NMC gets Medical Colleges to comply with PMR in MBBS it will be available in days perhaps
[1:24 AM, 6/10/2026] hu10: IMA and IAPMR have been shying off from their responsibility till now, but I hope they will be forced to do their task this month
[4:05 AM, 6/10/2026] hu10: https://www.linkedin.com/posts/ganesh-joshi-3849946_healthcare-quacks-halfbakeddoctors-ugcPost-7470241672120107008-ryZ6/?utm_source=share&utm_medium=member_android&rcm=ACoAAAE2ghQBjK5lO15tU56ZpW2a52Cm_ftnTNU
[6:20 AM, 6/10/2026] 42mpa: https://www.linkedin.com/posts/colbygillespie_patientfirst-continuum-health-survey-activity-7470275790585298944-tH8u?utm_medium=ios_app&rcm=ACoAAEcKPFQBS7zyp1iECYDDD76fM1irYNB86q8&utm_source=social_share_send&utm_campaign=copy_link
[10:57 AM, 6/10/2026] hu7: https://www.linkedin.com/posts/dravinashkumargupta_vibe-rounds-for-healthcare-ugcPost-7470343639722823680-1WvP/
[11:17 AM, 6/10/2026] hu2: Exciting future 👏
[11:18 AM, 6/10/2026] hu7: Telling in Fancy way live micro grand rounds (vibe coding + grand rounds)
[11:58 AM, 6/10/2026] hu35: Ownership has many different meanings. What exactly do you mean by it?
[12:13 PM, 6/10/2026] hu15: Meaning they should be proactive in their PaJR. So as to make the collaboration with the PaJR team successful
[12:51 PM, 6/10/2026] hu5: Anyone come across this? https://ddxof.com/
What a beautiful way of structuring patient stories and turning them into reusable artifacts.
[1.19 pm, 10/06/2026] hu1: Very similar to CP solvers and likely based on the Human Diagnosis Project.
